GO
Loading...

Novartis AG

More

  • Novartis sues India's Cipla over respiratory drug Onbrez Wednesday, 17 Dec 2014 | 8:22 AM ET

    MUMBAI, Dec 17- Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price. Cipla, India's fourth-largest drugmaker by revenue, launched its copy of Onbrez in New Delhi in October, citing urgent unmet need for the...

  • FRANKFURT, Dec 15- Bayer's eye medication Eylea does not offer an advantage over a rival product from Novartis when treating patients with a type of diabetes-related swelling of the retina, a German healthcare cost watchdog said on Monday. IQWiG compared trial data on Eylea and Novartis's Lucentis for treatment of diabetic macular edema and found there was no...

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • LONDON, Dec 8- Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. The Spark program is expected to enter early-stage clinical trials for hemophilia B in the first half of 2015. Spark will be responsible for the early Phase I/II tests, with...

  • Sandoz loses bid to shield psoriasis drug Friday, 5 Dec 2014 | 2:09 PM ET

    Dec 5- The top U.S. patent appeals court has upheld the dismissal of a lawsuit brought by Sandoz Inc that sought to shield its planned version of Amgen Inc's psoriasis and arthritis drug Enbrel from patent lawsuits. Taranto only ruled that the lawsuit against Amgen was premature because Sandoz had not yet sought approval for the drug from the U.S. Food and Drug...

  • Hawaiian Electric and Taser are big market movers Thursday, 4 Dec 2014 | 4:35 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:. Hawaiian Electric Industries Inc., up $4.03 to $32.22. Rite Aid Corp., up 12 cents to $5.58.

  • British drugmaker cutting hundreds of US jobs Thursday, 4 Dec 2014 | 4:01 PM ET

    Hundreds of British drugmaker GSK's 17,000 US-based employees will lose their jobs by the end of next year under the its restructuring plan.

  • LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. Bidders, who had been hoping to clinch a deal before the end of the year,...

  • British drugmaker cutting hundreds of US jobs Thursday, 4 Dec 2014 | 1:16 PM ET

    TRENTON, N.J.— Hundreds of British drugmaker GlaxoSmithKline's 17,000 U.S.-based employees will lose their jobs by the end of next year under the pharmaceutical industry's latest restructuring. GlaxoSmithKline PLC, best known for its widely used asthma inhaler Advair, is making changes worldwide that are meant to produce about $1.6 billion in annual...

  • LONDON, Nov 30- GlaxoSmithKline will this week inform U.S. staff of hundreds of job cuts in its biggest market as the drugmaker starts implementing a major cost-saving programme, sources familiar with the matter said on Sunday. Britain's top drugmaker announced at third-quarter results on Oct. 22 that the new restructuring scheme would save 1 billion pounds in...

  • WASHINGTON, Nov 26- Switzerland's Novartis AG has agreed to sell its nicotine patch, Habitrol, in order to win U.S. antitrust approval for a consumer healthcare joint venture with Britain's GlaxoSmithKline, the U.S. Federal Trade Commission said on Wednesday. The deal is part of a three-way transaction unveiled in April, which includes GSK buying Novartis'...

  • *Developed by UniQure and marketed in Europe by Chiesi. FRANKFURT/ LONDON, Nov 26- The Western world's first gene therapy drug is set to go on sale in Germany with a 1.1 million euro price tag, a new record for a medicine to treat a rare disease. The sky-high cost of Glybera, from Dutch biotech firm UniQure and its unlisted Italian marketing partner Chiesi, shows how...

  • *Buffett's Berkshire, Novartis, Givaudan doing well. But good news is emerging now for those who prefer safer strategies: some of the best returns this year have come from stable stocks like billionaire Warren Buffett's holding company Berkshire Hathaway or Swiss toilet maker Geberit. "Investors are ready to invest on the equity market but under the condition...

  • European shares erase gains ahead of Fed minutes Wednesday, 19 Nov 2014 | 12:35 PM ET

    LONDON, Nov 19- European shares ended flat after hitting a seven-week high earlier on Wednesday, with investors trading cautiously ahead of minutes from the most recent Federal Reserve policy meeting. The market also faced pressure from a sharp decline in mining shares after China's iron ore futures dropped nearly 5 percent to a record low.

  • European shares edge lower ahead of Fed minutes Wednesday, 19 Nov 2014 | 11:24 AM ET

    LONDON, Nov 19- European shares edged lower from a seven-week high late on Wednesday, tracking a fall in U.S. equities, with investors trading cautiously ahead of minutes from the most recent Federal Reserve policy meeting. The market also came under pressure from a sharp decline in mining shares after China's iron ore futures dropped nearly 5 percent to a record...

  • European shares advance, Swiss index hits 9,000 Wednesday, 19 Nov 2014 | 8:48 AM ET

    LONDON, Nov 19- The pan-European FTSEurofirst 300 share index climbed to a seven-week high on Wednesday, helped by broker upgrades, and Switzerland's SMI equity index hit the 9,000 mark for the first time since late 2007.. Prudential rose 1.3 percent after Deutsche Bank increased its target price for the stock to 1,680 pence from 1,630 pence, Severn Trent was up...

  • European shares edge higher, Swiss index hits 7-year high Wednesday, 19 Nov 2014 | 6:09 AM ET

    LONDON, Nov 19- European shares turned positive in morning trading on Wednesday, helped by some encouraging broker upgrades, with Switzerland's SMI equity index hitting the 9,000- point mark for the first time since late 2007.. Prudential rose 1.1 percent to lead insurers after Deutsche Bank increased its target price for the stock to 1,680 pence from 1,630...

  • CHICAGO, Nov 17- An experimental heart failure medicine from Novartis that previously showed it reduced death and hospitalizations also curtailed worsening of symptoms, need for additional therapy and emergency room visits, adding to evidence that it will become the drug of choice once approved. The Novartis drug, expected to become a multibillion-dollar...